A study conducted by Beike Biotechnology Company ( http://www.beikebiotech.com ) in conjunction with physicians and researchers at two Chinese hospitals, documents the effectiveness of cord blood-derived stem cells in treating primary biliary cirrhosis (PBC). The study, which was published in the April 2012 issue of the Stem Cell Discovery, was the first of its kind. Researchers noted that additional clinical trials would be required before stem cells can become an accepted therapy for liver cirrhosis.
Prof. Jin-hui Yang, Director of the Department of Hepatology in the 2nd Affiliated Hospital of Kunming Medical College stated, “Given the severity of liver cirrhosis
The King Abdulaziz Medical City in Riyadh is getting ready to open a stem cell bank harvested from the umbilical cord. The procedure will be done in laboratories and specially equipped rooms to draw the cells from umbilical cord blood and separate them using a special device.
Then they will be stored in labs for a period from 15 to 20 years after examining them and making sure they are free of contagious and genetic diseases. In addition, a team will be prepared for coordinating, marketing and research within this field.
The same genes that are chemically altered during normal cell differentiation, as well as when normal cells become cancer cells, are also changed in stem cells that scientists derive from adult cells, according to new research from Johns Hopkins and Harvard.
Although genetically identical to the mature body cells from which they are derived, induced pluripotent stem cells (iPSCs) are notably special in their ability to self-renew and differentiate into all kinds of cells. And now scientists have detected a remarkable if subtle molecular disparity between the two: They have distinct “epigenetic” signatures; that is, they differ in what gets
Transplanting own stem cells into heart of severe angina patients lessens their pain and improves their ability to walk, a new study has revealed.
The largest national stem cell study for heart disease showed that transplant subjects also experienced fewer deaths than those who didn’t receive stem cells.
In the 12-month Phase II, double-blind trial, subjects’ own purified stem cells, called CD34+ cells, were injected into their hearts in an effort to spur the growth of small blood vessels that make up the microcirculation of the heart muscle (…)
He also said that this study provides the first evidence that a person’s
TaiGen Biotechnology Co., Ltd. announced today that in a phase 1 study in healthy volunteers TG-0054, a chemokine receptor CXCR4 antagonist, was well tolerated and rapidly mobilized stem cells and endothelial progenitor cells from bone marrow into peripheral blood. The number of CD34+ stem cells in circulation after one dose of TG-0054 was equal or higher than reported cell numbers needed for stem cell transplantation in cancer patients. The observed AEs were all mild and transient. A phase 2 study in stem cell transplantation for multiple myeloma, non-Hodgkin lymphoma and Hodgkin disease patients is currently being initiated (…)